KEYNOTE-100: Final Results From Phase II Study on Pembrolizumab Monotherapy for Advanced Recurrent Ovarian Cancer

From Clinical Care Options (CCO), Webcast and downloadable slides reviewing the latest data on the use of PARP inhibitors to treat newly diagnosed advanced ovarian cancer

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci
Program Director Alexandra Leary, MD, PhD Frederik Marmé, MD, PhD Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Released: February 19, 2021 Expired: February 18, 2022

On-demand Clinical Care Options (CCO) Webcast that reviews the latest clinical data informing the optimal management of patients with ovarian cancer from an expert global perspective.

Antonio Gonzalez-Martin, MD, PhD Ursula Matulonis, MD Prof Ignace Vergote Released: February 11, 2021

Expert commentary on the use of PARP inhibitors as frontline maintenance therapy in the treatment of ovarian cancer, from Clinical Care Options

Ursula Matulonis, MD Released: January 11, 2021

In this slideset, CCO’s expert faculty explores the role of biomarkers and HRD when treating patients with ovarian cancer using PARP inhibitors

Alexandra Leary, MD, PhD Released: December 22, 2020